Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Trial to Compare the Efficacy, Safety and Tolerability of DRV/Rtv (800mg/100mg) q.d Versus DRV/Rtv (600mg/100mg) b.i.d in Early Treatment-experienced HIV-1 Infected Subjects

NCT00524368 is registered in ClinicalTrials.gov with Tibotec Pharmaceuticals, Ireland as lead sponsor.

NCT NCT00524368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00524368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Trial to Compare the Efficacy, Safety and Tolerability of DRV/Rtv (800mg/100mg) q.d Versus DRV/Rtv (600mg/100mg) b.i.d in Early Treatment-experienced HIV-1 Infected Subjects
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2007
Completion date
October 31, 2011
Enrollment
590 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus - type 1